Thumbs Up

News

Get a Medical Diagnosis Using Facetime!

January 21, 2019

Tailoring Medical Prescriptions Can Help Fight the Opioid Crisis

January 17, 2019

How Artificial Intelligence is Shaping Personal Health in 2019

January 15, 2019

8 Healthcare Predictions for 2019

January 11, 2019

How Millennials are Changing the Healthcare Industry

January 9, 2019

 

What Changes Have Been Made to Medicare for 2019?

January 7, 2019

What Happens if You Don't Have Health Insurance in 2019?

January 4, 2019

What is Changing & What's Staying the Same with the ACA

January 2, 2019

A Healthcare System That Works for Everyone: Improving Cost Containment in the U.S.

October 22, 2018

The Medliminal Washington Report 5.31.18

May 31, 2018

  The House and Senate spent their final week in Washington before recessing until June 5 working on competing versions of legislation to address the opioid epidemic. The Senate Judiciary Committee voted to send five opioid-related bills to the floor, days after the House Energy and Commerce Committee approved a package of 30+ bills. The House also passed so-called “right to try” legislation, incorporating Senate revisions to an earlier bill that now awaits the president’s signature. Secretary of Health and Human Services Alex Azar continues to amp up his rhetoric against drug makers in advance of a June 12 Senate hearing on the president’s recently-revealed drug price proposals. The Congressional Budget Office released reports on the impact of proposed federal regulations governing association and short-term health plans, and projected exchange premiuns in 2019. We break it all down in this week’s health care review.

The Medliminal Washington Report 5.22.18

May 22, 2018

Following the president’s public release of the 44-page blueprint outlining the administration’s strategy and priorities, senior administration officials have been busy implementing initial steps. The Secretary of Health & Human Services outlined regulatory steps that he could take without congressional action such as changing drug rebates or changes to Medicare reimbursement. The Food and Drug

The Medliminal Washington Report 5.16.18

May 16, 2018

The president finally delivered his much-anticipated address on prescription drug prices, and released a 44-page blueprint outlining the administration’s strategy and priorities. While the speech was criticized by some for not offering proposals targeting drug makers or health plans, the blueprint envisions future regulatory actions, so this will be an ongoing issue to monitor in

The Medliminal Washington Report 5.7.18

May 7, 2018

Both house of Congress return from their week long recess, and has been the case for the last month, the nation’s opioid epidemic will be front and center. Three House subcommittees will hold hearings focused on different aspects of the crisis and the full House Energy and Commerce Committee has scheduled mark ups for the 50+

CMS price transparency NPR

May 2, 2018

On April 24, 2018, the Centers for Medicare and Medicaid Services (CMS) released an 1883-page proposed rule that, in addition to many other policy goals, seeks to increase price transparency and make electronic health records more interoperable. Specifically, the proposed rule – the FY 2019 Medicare Hospital Inpatient Prospective Payment System and Long Term Acute

The Medliminal Washington Report 5.1.18

May 1, 2018

The House and Senate spent their final week in Washington before recessing until May 7 working on competing versions of legislation to address the opioid epidemic. A Senate committee unanimously passed a wide-ranging bill, while a House committee passed 57. Both chambers are hoping to have a bill passed and to the president’s desk sometime

The Medliminal Washington Report 4.24.18

April 24, 2018

The health care policy focus in Washington this week will again center on House and Senate efforts to confront the opioid epidemic. Both committees of jurisdiction in the House and Senate are moving on opioid legislation, with an unofficial timetable of Memorial Day to have a bill passed out each chamber and to the president’s

The Medliminal Washington Report 4.16.18

April 16, 2018

The U.S. House and Senate returned from the Easter recess on April 9 with the focus expected to be on the nation’s opioid epidemic. While there were a number of committee hearings on both sides of Capitol Hill, any legislative news of the week was surpassed by the announcement by House Speaker Paul Ryan that

The Medliminal Washington Report 4.11.18

April 11, 2018

  The U.S. House and Senate return from their two-week recess on April 9 with its eyes set on addressing the opioid epidemic. We expect to see some form of bipartisan legislation considered before Memorial Day. The Centers for Medicare and Medicaid Services recently released the final exchange enrollment figures for 2018, which showed a minor

Medliminal Submits Comments in Support of Senate Price Transparency Initiative

April 6, 2018

  Medliminal CEO James Napoli today submitted comments to Senators Bill Cassidy (R-LA), Michael Bennet (D-CO), Chuck Grassley (R-IA), Tom Carper (D-DE), Todd Young (R-IN) and Claire McCaskill (D-MO) as they develop legislation to improve health care price transparency and ultimately lower costs.

The Medliminal Washington Report 4.2.18

April 2, 2018

The U.S. House and Senate remain on Easter recess, but return to Washington on April 9. The Centers for Medicare and Medicaid Services boosted Medicare Advantage payments and the Secretary of Health and Human Services named a new advisor for drug price reforms. Also, health care consolidation looks continue with Walmart reportedly considering an acquisition